Berberine exhibits a broad spectrum of pharmacological activities that collectively influence key metabolic disturbances associated with obesity, insulin resistance, glucose homeostasis, and lipid metabolism, underscoring its potential as a multifaceted therapeutic agent in metabolic disorders. The gene discussed is INS; the disease is metabolic disease.